It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Central Java reported 1,541 cases of Patients Under Surveillance until April 14th, 2020. It is expected to increase everyday. However, reports about the epidemiological characteristics of Patients Under Surveillance cases are still limited. This study aims to describe Patients Under Surveillance case of COVID-19. The study used quantitative descriptive design, whereas many as 1,541 cases were described based on the characteristics, contact history, history of transit, and the symptoms. The data are obtained from the Department of Health, Central Java and processed with descriptive statistical data analysis. Results showed from 1,541 cases as much as 59.9% were male and 43% aged 19-44 years. As many as 154 death cases were dominated by men (61.6%) and elderly ≥60 years (38.3%). The highest IR was Semarang (16.85/100,000 population). Symptoms that often found were cough, fever, dyspnea (8.3%), and 3.96% asymptomatic. The history of contact with the traveling person (4.7%). The most visited city was Jakarta (7.5%). It is concluded that cases in Central Java spread across 35 cities with a high number of cases and mortality. It is necessary to conduct a detailed Patients Under Surveillance case reports to monitor the spread of the virus that can be prevented in advance.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer